Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activities of Anti-PD-1 Monoclonal Antibody BGB-A317 in Chinese Patients With Advanced Solid Tumors

NCT04068519 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04068519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04068519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activities of Anti-PD-1 Monoclonal Antibody BGB-A317 in Chinese Patients With Advanced Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Completed
Start date
December 28, 2016
Completion date
May 31, 2020
Enrollment
300 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors